Other Clinical Trial - Observational Real-life Study of Cabozantinib in

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT04043975` - A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan
	Completed	`NCT00873210` - Study In Patients With Kidney Cancer Treated With Sutent	N/A

See also

Status

Clinical Trial

Phase

Active, not recruiting

NCT04043975 - A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan

Completed

NCT00873210 - Study In Patients With Kidney Cancer Treated With Sutent

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04106349
Study type	Observational
Source	Ipsen
Contact	Ipsen Recruitment Enquiries
Phone	see email
Email	clinical.trials@ipsen.com
Status	Recruiting
Phase
Start date	March 3, 2020
Completion date	June 30, 2026

Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC) — REPLICA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms